Eli Lilly prepares for FDA rejection of eczema treatment

Following two delays to the FDA’s final decision, Eli Lilly now says that the approval of a new indication in the US might not be in the cards for its eczema drug for adults, Olumiant.

Photo: Darron Cummings/AP/Ritzau Scanpix

Eli Lilly’s tug-of-war with the US Food and Drug Administration (FDA) over the treatment for adults with atopic eczema, Olumiant (baricitinib), is currently not looking to end favorably for the US-based pharmaceutical company.

In a news release, Eli Lilly warns its investors and the public that the company’s supplemental marketing application filed with the FDA could now end up in a rejection – a so-called ”complete response letter.”

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs